Literature DB >> 18186813

Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.

K Brockow1, C Jofer, H Behrendt, J Ring.   

Abstract

BACKGROUND: Excessive mast cell mediator release may lead to anaphylaxis in patients with mastocytosis. However, the incidence, clinical features and trigger factors have not yet been analyzed.
METHODS: To identify risk factors for anaphylaxis in mastocytosis, we determined cumulative incidence, severity, clinical characteristics, and trigger factors for anaphylaxis in 120 consecutive patients (53 male; 67 female, median age and range 24 years, 1 month to 73 years), and correlated these with disease severity of mastocytosis, skin involvement, basal total serum tryptase, and diaminooxidase concentrations.
RESULTS: The cumulative incidence of anaphylaxis in patients with mastocytosis was higher in adults (49%; P < 0.01) compared with that in children (9%). Only children with extensive skin involvement had experienced anaphylaxis. In adults, anaphylaxis was correlated to the absence of urticaria pigmentosa lesions (P < 0.03). Reactions occurred more frequently in adults with systemic (56%) when compared with cutaneous mastocytosis (13%; P < 0.02). In adults, 48% of reactions were severe, and 38% resulted in unconsciousness. Major perceived trigger factors for adults were hymenoptera stings (19%), foods (16%), and medication (9%); however, in 26% of reactions, only a combination of different triggers preceded anaphylaxis. Trigger factors remained unidentified in 67% of reactions in children compared with 13% in adults. Patients with anaphylaxis had higher basal tryptase values (60.2 +/- 55 ng/ml, P < 0.0001) in comparison with those without (21.2 +/- 33 ng/ml), but not diaminooxidase levels.
CONCLUSION: Adult patients and children with extensive skin disease with mastocytosis have an increased risk to develop severe anaphylaxis; thus, an emergency set of medication including epinephrine is recommended.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18186813     DOI: 10.1111/j.1398-9995.2007.01569.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  108 in total

1.  Exercise-induced anaphylaxis.

Authors:  Taro Shimizu; Yasuharu Tokuda
Journal:  BMJ Case Rep       Date:  2012-05-30

Review 2.  Eosinophilic myeloproliferative disorders.

Authors:  Amy D Klion
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

3.  Mast cell activation syndrome: Proposed diagnostic criteria.

Authors:  Cem Akin; Peter Valent; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2010-10-28       Impact factor: 10.793

Review 4.  Hereditary Alpha-Tryptasemia: a Commonly Inherited Modifier of Anaphylaxis.

Authors:  Richard Wu; Jonathan J Lyons
Journal:  Curr Allergy Asthma Rep       Date:  2021-05-10       Impact factor: 4.806

Review 5.  The Role of KIT Mutations in Anaphylaxis.

Authors:  Elise Coulson; Sherry Zhou; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2019-04-26       Impact factor: 4.806

6.  Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

Authors:  Eunice Ching Chan; Yun Bai; Arnold S Kirshenbaum; Elizabeth R Fischer; Olga Simakova; Geethani Bandara; Linda M Scott; Laura B Wisch; Daly Cantave; Melody C Carter; John C Lewis; Pierre Noel; Irina Maric; Alasdair M Gilfillan; Dean D Metcalfe; Todd M Wilson
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

Review 7.  [Emergency treatment and management of anaphylaxis].

Authors:  K Brockow; J Ring
Journal:  Hautarzt       Date:  2013-02       Impact factor: 0.751

Review 8.  The tyrosine kinase network regulating mast cell activation.

Authors:  Alasdair M Gilfillan; Juan Rivera
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  Adrenaline in the Acute Treatment of Anaphylaxis.

Authors:  Johannes Ring; Ludger Klimek; Margitta Worm
Journal:  Dtsch Arztebl Int       Date:  2018-08-06       Impact factor: 5.594

10.  Recent advances in mast cell clonality and anaphylaxis.

Authors:  Cem Akin
Journal:  F1000 Med Rep       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.